HDAC9 and acute myeloid leukemia: As RBBP4 is an important component of the HDAC complex, AML with low RBBP4 expression will be more sensitive to HDAC inhibitors, and its expression is expected to be an indicator for the use of HDAC inhibitors (Khateb et al., 2021).